• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

GSK told to pay higher royalties to AZ on Zejula sales

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 06, 2023 at 11:52: AM
via A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ovarian cancer drug Zejula, which competes with AZ’s top-selling PARP inhibitor Lynparza.

article source
 




Top Bottom
Back
Quote